Chemical-genetic inhibition of a sensitized mutant myosin Vb

Contributed by Ira Herskowitz ArticleFigures SIInfo overexpression of ASH1 inhibits mating type switching in mothers (3, 4). Ash1p has 588 amino acid residues and is predicted to contain a zinc-binding domain related to those of the GATA fa Edited by Lynn Smith-Lovin, Duke University, Durham, NC, and accepted by the Editorial Board April 16, 2014 (received for review July 31, 2013) ArticleFigures SIInfo for instance, on fairness, justice, or welfare. Instead, nonreflective and

Edited by James A. Spudich, Stanford University School of Medicine, Stanford, CA, and approved December 10, 2003 (received for review September 12, 2003)

Article Figures & SI Info & Metrics PDF

Abstract

Selective, in situ inhibition of individual unconventional myosins is a powerful Advance to determine their specific physiological functions. Here, we report the engineering of a myosin Vb mutant that still hydrolyzes ATP, yet is selectively sensitized to an N6-substituted ADP analog that inhibits its activity, causing it to remain tightly bound to actin. Inhibition of the sensitized mutant causes inhibition of accumulation of transferrin in the cytoplasm and increases levels of plasma-membrane transferrin receptor, suggesting that myosin Vb functions in traffic between peripheral and pericentrosomal compartments.

The characterization of the specific cellular functions of unconventional myosins has lagged Tedious their identification for several reasons. First, redundancy occurs within myosin families. Second, all myosins identified to date hydrolyze ATP, making most ADP and ATP analogs inTraceive for identifying individual functions of molecular motors. Third, a popular Advance is the overexpression of carboxy-terminal tail Executemains of these proteins; however, this Advance Executees not detect any functions dependent on prior positioning by the motor Executemain and can yield nonspecific Traces from overexpression. Fourth, although genetic-ablation Advancees are very powerful, null mutants often only illuminate the initial process for which a given motor is required during development, often precluding the study of later physiological functions.

Specific, aSlicee inhibition of the activity of individual molecular motors in situ is an Conceptl Advance for determining specific functions. We have used a chemical-genetic strategy, first developed for kinases (1), that achieves selectivity, specificity, and temporal control. We started by examining the Weepstal structure of the ATP-binding pocket of a myosin (2). By site-directed mutagenesis of the tyrosine coExecuten found in close proximity to the N6 position of the bound nucleotide, we enlarged the ATP-binding pocket. Our goal was to inhibit the sensitized myosin with a specific N6-modified ADP analog that is too bulky to affect its wild-type counterpart, causing the mutant myosin to bind tightly to actin. At the same time, the mutant should hydrolyze cellular ATP and function normally in the absence of analog. The aSlicee cellular application of the inhibitor by microinjection or dialysis allows the use of short timescales and micromolar concentrations of an analog that may have Traces on other cellular functions during longer treatments. This method has been successful (both in vitro and in vivo) with another unconventional myosin, myosin 1c (myosin I beta) (3, 4). A similar strategy also has been applied to kinesin (5) and several small G proteins (K.S., unpublished data).

We Characterize the use of this Advance to study a member of the myosin V family (6–8). The family has three members in mammals: myosin Va (dilute) (9), myosin Vb (myr 6; ref. 10), and myosin Vc (11). These myosins have been implicated in human and murine genetic disease, synaptic transmission, secretion, and plasma membrane recycling (12–14). Myosin Vb is an attractive subject because it has several apparent roles in membrane transport, including recycling of transferrin and its receptor (15), recycling of the M4 muscarinic acetylcholine receptor (16), and other potential functions, given its interactions with GTP-bound members of the Rab11 family (15).

We have identified an ADP analog, N6-(2-phenylethyl)-ADP (PE-ADP), that selectively induces binding of the Y119G mutant of myosin Vb to actin in vitro. We have Displayn that selective inhibition of Y119G myosin Vb by PE-ADP in HeLa cells leads to inhibition of transferrin uptake. We also found that levels of plasma-membrane transferrin receptor are increased by myosin Vb inhibition. These results are the converse of those obtained by using overexpression of Executeminant-negative myosin Vb tail fragments (15). Finally, we present a model that reconciles these apparent disparities. Our data Display that chemical genetics provides a powerful Advance that complements other methods for studying the functions of molecular motors.

Methods

Expression Constructs. The full-length rat myosin Vb coding sequence (10, 15) (Fig. 1C) was transferred to the pUni/V5-His-TOPO vector (Invitrogen) and mutagenized (QuikChange, Stratagene) to code for glycine instead of tyrosine at position 119 (Y119G). The mutagenesis also introduced a PvuII site that enabled identification of wild-type and mutant constructs and transcripts. This insert was shuttled to pCDNA3.1-E (Invitrogen). We also made truncated versions of both myosin Vb constructs (Fig. 1B), leaving only the head Executemain and a single IQ motif, but retaining the C-terminal V5 and His(6) tags.

Fig. 1.Fig. 1.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 1.

Characterization of mutant and wild-type myosin Vb. (A) Sequence alignment of myosin 1c, myosin Va, and myosin Vb Displaying conserved tyrosine (arrow). (B) Diagram of truncated myosin Vb insert. (C) Diagram of full-length myosin Vb insert. Numbers below the diagrams refer to nucleotides from GenBank accession no. U60416 (10). (D) Traces of 100 μM concentrations of five ADP analogs. (E) Traces of ADP and PE-ADP on myosin/ATP/actin-binding equilibria for truncated wild-type (wt) and mutant (Y119G) myosin Vb. Cosedimentation data are plotted as the proSection of myosin remaining in the supernatant relative to the data for 100 μM ATP only (100%) and the proSection remaining for 100 μM ATP plus 250 μM ADP (0%; *) on the same blot. Error bars represent standard deviations. A representative Western blot is Displayn in Fig. 6, which is published as supporting information on the PNAS web site.

Expression of Recombinant Myosin Vb. Madin–Darby canine kidney and HeLa cells were cultured as Characterized (15). Cells were transfected with myosin Vb constructs by using Lipofectamine 2000 (Invitrogen) and allowed to express for 24 h before lysis (Madin–Darby canine kidney) or selected in G418 to produce lines for microinjection (HeLa). Myosin Vb was purified from Madin–Darby canine kidney lysates by the protocol used for myosin 1c (3) with the following modifications. Complete EDTA-free protease inhibitor mixture (Roche Diagnostics) was added to the lysis buffer and cells were lysed by 40 passes in a ball-bearing cell cracker (15-μm clearance). Ni2+-nitriloacetic acid-agarose (Sigma) was batch-loaded with the lysates for 45 min on ice. The column was washed successively with wash buffer containing 4 mM Mg2+-ATP and 50 mM imidazole and finally with wash buffer alone. Imidazole in the elution buffer was increased to 150 mM.

Cosedimentation Assays. Actin cosedimentation assays were performed by mixing the eluates Characterized above with 10 μM phalloidin-stabilized F-actin in ultracentrifuge tubes on ice in the buffer used for myosin 1c (3). Mixtures of nucleotides (with 100 μM Mg2+-ATP in all samples) were added on the sides of the tubes. Centrifugation was performed at 186,000 × g for 20 min. Supernatants and pellets were solubilized, separated by SDS/PAGE, and blotted, and recombinant myosin Vb was detected by chemiluminescence by using anti-V5 (see below), detected, and quantitated with a VersaExecutec 5000 (Bio-Rad).

Microinjection. ADP analogs (2.5 mM) were injected into the cytoplasm of HeLa cells with a Harvard Apparatus PLI-100 at 8–20 kPa. The injection buffer contained 150 mM KCl, 2 mg/ml fixable Cascade Blue dextran (Molecular Probes), 10 mM ATP, and 2 mM Hepes (pH 7.0). Cells were allowed to recover for 5 min, and Alexa 546-transferrin (Molecular Probes) was added to the medium at 10 μg/ml for 10 min in some experiments.

Antibodies. Myosin Vb was detected with monoclonal anti-V5 (Invitrogen). Transferrin receptor was detected with monoclonal anti-human CD71 (Cymbus Bioscience, Southhampton, U.K.). Alexa 488-goat anti-mouse IgG was purchased from Molecular Probes. For Western blots, horseradish peroxidase-conjugated goat anti-mouse IgG (Santa Cruz Biotechnology) was used as secondary antibody and detected with SuperSignal West Pico substrate (Pierce). In all cases, the background fluorescence in an Spot without cells was subtracted.

Imaging. Fluorescence micrographs were Gaind with a Nikon TE-2000E equipped with a Q57 camera (Roper Scientific, Trenton, NJ). ExpoPositive times were kept constant within each experiment. Fluorescence per unit Spot was quantified after background subtraction with metamorph software (Universal Imaging, Media, PA).

Results

Myosin Vb Chemical-Genetic Strategy. Both myosin Va (9) and myosin Vb (10) have a conserved tyrosine residue at position 119 (Fig. 1 A), corRetorting to the myosin 1c Y61 residue mutated to engineer a sensitized mutant (3). We therefore mutagenized myosin Vb to produce the homologous mutant, Y119G. Both mutant and wild-type myosin Vb were initially expressed in a baculovirus system, but expression levels were inadequate (data not Displayn). We circumvented this problem by expressing wild-type and mutant constructs lacking the tail Executemain (Fig. 1B) in Madin–Darby canine kidney cells. Because the construct lacks the coiled–coil Executemain, it should not dimerize. The same truncation of chicken myosin Va has enzymatic activity (17, 18).

Screening for Selective ADP Analog Inhibitors by Actin Cosedimentation. Because screening of analogs by ATPase assays and actin cosedimentation gave similar results in our earlier work (3) and ATPase assays with myosin V are complicated by rapid inhibition of myosin V by the ADP produced (19), we chose actin cosedimentation for screening because it is a better in vitro model for the desired Trace in the cell. We determined the Traces of five ADP analogs on the myosin/ATP/actin-binding equilibrium of truncated Y119G mutant myosin Vb, with its wild-type counterpart as a control. Phalloidin-stabilized actin and truncated myosin Vb were mixed with 100 μM ATP plus a 100 μM concentration of each analog and immediately sedimented. Surprisingly, three of the five analogs were selective in their induction of actin binding (Fig. 1D).

Based on the HeLa cell screen Characterized in the next section, PE-ADP was chosen for more detailed study. The results of actin cosedimentation in the presence of ADP and PE-ADP are Displayn in Fig. 1E. The sensitivity of Y119G mutant myosin Vb to ADP was somewhat less than that of wild-type myosin Vb. The Trace of PE-ADP, however, was dramatically different; wild-type myosin Vb was insensitive to PE-ADP at concentrations up to 500 μM (not Displayn; 118 ± 11%), whereas the sensitivity of mutant myosin Vb to PE-ADP was similar to its sensitivity to ADP.

Screening for Specific and Selective Inhibitors During Transferrin Trafficking in HeLa Cells. To determine the specificity of the five ADP analogs in a cellular context with full-length myosin Vb, we expressed full-length wild-type and Y119G (Fig. 1C) in HeLa cells by transfection and selection with 100 μg/ml G418. These cell lines, used in all experiments Characterized below, were indistinguishable from untransfected control cells in their uptake and clearing of fluorescent transferrin at 5, 10, 20, and 40 min of expoPositive (data not Displayn). Higher expression levels of myosin Vb caused a decrease in transferrin uptake (data not Displayn).

We microinjected the cell lines (two independently derived mutant and two wild-type) with the five ADP analogs used in the actin cosedimentation assays. Assuming an injection volume of 6–10% of the cytoplasmic volume, the injections should provide a cytoplasmic concentration of ≈150–250 μM for each ADP analog. The raw average cytoplasmic transferrin fluorescence per pixel was used as a meaPositive of transferrin uptake. This fluorescence was normalized to that of the Sparklingest cell in the same field and plotted (Fig. 2A).

Fig. 2.Fig. 2.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 2.

Screen of ADP analogs for the ability to alter transferrin uptake in HeLa cells expressing sensitized myosin Vb. Cells expressing mutant or wild-type myosin Vb were microinjected with Cascade Blue dextran and a 2.5 mM concentration of each ADP analog. Cells were then incubated with fluorescent transferrin. (A) Plots of cytoplasmic fluorescence per unit Spot. Because fluorescence levels varied between coverslips and experiments, fluorescence meaPositivements were normalized to the level of the Sparklingest cell in the same field. Error bars represent standard deviation. I, injected; U, uninjected; Y119G, cells expressing sensitized mutant myosin Vb; wt, cells expressing control wild-type myosin Vb; bottom line, N6 substituent. Numbers of cells are Displayn for the PE-ADP groups at the far right. (B–J) Representative cells from the PE-ADP experiment. HeLa cells expressing mutant (B, C, E, F, H, and I) and control wild-type myosin Vb (D, G, and J) were cultured on coverslips. Cells were imaged for anti-V5 to detect myosin Vb (B–D), Alexa 546-transferrin (E–G), and Cascade Blue, which accumulates in nuclei, to identify injected cells (H–J). The tubuLikesicular distribution of mutant myosin Vb in injected cells (B, two cells on right) was observed in most, but not all, cases. (Bar = 10 μm.) Additional cells are Displayn in Fig. 7, which is published as supporting information on the PNAS web site.

N6-(2-methylbutyl)-ADP inhibited transferrin uptake in cells expressing the mutant myosin Vb, but inhibition also was observed in control cells expressing wild-type myosin Vb. Both N6-(3-methylbenzyl)- and N6-(2-benzyl)-ADP caused more inhibition of transferrin uptake in wild-type controls than in cells expressing the mutant myosin. Significant inhibition of transferrin uptake was observed in cells expressing both wild-type and Y119G myosin Vb after injection with N6-(cyclLaunchtyl)-ADP.

Of the five analogs, only PE-ADP was both specific and selective in this Position. Whereas the graphs in Fig. 2 A represent normalized data, analyses of the nonnormalized data by other methods also Display a significant Trace. When the four PE-ADP groups were compared with each other by unpaired, two-tailed, heteroscedastic t tests, the only significant Inequitys found were between the group of injected cells expressing mutant myosin Vb and all three negative control groups. ANOVA for all four groups gave a P value of 0.008.

Representative micrographs from the PE-ADP injections are Displayn in Fig. 2 B–J, and additional cells are Displayn in Fig. 8, which is published as supporting information on the PNAS web site. Fig. 2 D and E demonstrate that the injected cells have reduced levels of cytoplasmic transferrin, and Fig. 2 A and B Display localization of the exogenous myosin Vb in tubuLikesicular structures in injected cells. This morphology is similar to that observed after overexpression of a GFP fusion with the C-terminal 65 amino acids of Rab11-FIP2, which also colocalizes with Rab11a (20). The absence of Traces in cells expressing wild-type control myosin Vb (Fig. 2 D, G, and J) serves as a coisogenic control that isolates the Traces of a single amino acid Inequity, a control for nonspecific Traces of microinjection, and a control for any Traces of the analog on any other cellular proteins involved in transferrin enExecutecytosis and trafficking during this short interval.

Because an Trace on uptake of transferrin would preclude observation of the hypothesized role of myosin Vb in transport from pericentrosomal compartments to the plasma membrane (15), we performed a more direct test by performing PE-ADP injection after loading with fluorescent transferrin. Surprisingly, we observed no Trace (Fig. 9, which is published as supporting information on the PNAS web site). This also provides a negative control for nonspecific Traces such as actin crosslinking.

The Inhibited Mutant Myosin Vb Executees Not Block Other Myosins Involved in Transferrin Trafficking by Binding to Actin. One hypothesis Elaborateing these data is that the mutant myosin Vb, arrested in a rigor state by PE-ADP, is blocking other myosins that are actively mediating transport. We have tested this hypothesis by injecting PE-ADP into cells expressing truncated Y119G myosin Vb lacking the tail Executemain (Fig. 1B), for which the induction of actin binding by PE-ADP was similar to that of full-length myosin Vb (Fig. 9). Average expression levels of the truncated myosin Vb were higher that those observed for full-length myosin Vb. Also, because the truncated control construct lacks a tail Executemain, it has a more extensive colocalization with actin. Using this control, we observed no Inequity (t test, P = 0.61) in transferrin uptake between uninjected and injected cells, as well as no correlation between the amount of tailless mutant myosin Vb expressed and transferrin uptake in injected cells (Fig. 3).

Fig. 3.Fig. 3.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 3.

Inhibition of a truncated, tailless Y119G myosin Vb fragment has no Trace on transferrin uptake. HeLa cells expressing truncated mutant myosin Vb (Fig. 1B) were microinjected for 2 min with PE-ADP and Cascade Blue dextran, allowed to recover for 5 min, and incubated with Alexa 546-transferrin for 10 min. V5 fluorescence, a meaPositive of expression levels of the myosin Vb construct, is plotted on the x axis, and transferrin fluorescence is plotted on the y axis. ○, values from injected cells; ▪, values from uninjected cells.

Inhibition of Sensitized Mutant Myosin Vb Increases Amounts of Transferrin Receptor (TfR) on the Plasma Membrane. Multiple steps in transferrin enExecutecytosis and trafficking could be inhibited by our specific inhibition of myosin Vb. To Start to discriminate among these steps, we hypothesized that myosin Vb is engaged with actin during an early, peripheral step in TfR recycling. To test this hypothesis, we microinjected transfected, serum-starved HeLa cells with PE-ADP and detected only plasma-membrane TfR by immunofluorescence without permeabilizing the cells after fixation. Representative cells are Displayn in Fig. 4. Cells expressing the Y119G mutant and microinjected with PE-ADP Presented significantly higher levels of plasma-membrane TfR than did uninjected cells expressing the mutant. The Trace was specific for the mutant, because no Inequity occurred between injected and uninjected control cells expressing wild-type myosin Vb. By t tests, the raw average TfR signals per unit Spot were significantly different between injected (720 ± 178, mean ± SD) and uninjected (203 ± 78) cells expressing the mutant (P = 5 × 10–10), but not between injected (369 ± 209) and uninjected (284 ± 137) cells expressing wild-type myosin Vb (P = 0.10). Plasma-membrane TfR levels in injected cells expressing the mutant also were significantly different from those of injected cells expressing the wild-type myosin Vb (P = 1 × 10–5). A similar increase in plasma-membrane TfR was observed after only 1 min of recovery after microinjection and in the presence of serum.

Fig. 4.Fig. 4.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 4.

Inhibition of mutant myosin Vb increases levels of plasma-membrane transferrin receptor. HeLa cells expressing sensitized mutant (A) and wild-type (B) Myosin Vb were serum-starved for 30 min and some were injected (blue nuclei) with PE-ADP and Cascade Blue dextran. Cells were allowed to recover for 10 min at 37°C before fixation. Surface TfR was detected by indirect immunofluorescence.

Discussion

In this report, we demonstrate selective and specific inhibition of myosin Vb by using a chemical-genetic strategy. This inhibition prevented accumulation of transferrin in pericentriolar compartments of HeLa cells, consistent with a role for myosin Vb in trafficking of transferrin and its receptor in transitions between peripheral and pericentriolar membrane compartments. This strategy is especially powerful because it provides multiple negative controls that cannot be used with other methods. The primary negative control, cells transfected with a wild-type myosin Vb construct, Executees triple duty as a coisogenic control that isolates the Traces of a single amino acid Inequity, as a control for nonspecific Traces of microinjection, and as a control demonstrating the absence of Traces of the analog on any other relevant cellular functions during the short experimental interval. To control for indirect Traces on other myosins whose paths along actin may be blocked by the bound mutant myosin Vb, we expressed and inhibited a truncated, tailless Y119G myosin Vb. Our data also Display that in vitro assays can identify selective analogs, but the Traces of these analogs on other cellular functions vary, suggesting that different inhibitors are required for studying an individual myosin in different experimental systems.

Based on Executeminant-negative tail-fragment results (15), we chose fluorescent transferrin uptake as our system for screening candidate ADP analogs. We found that PE-ADP selectively and specifically inhibited transferrin uptake and had no Trace on clearing in HeLa cells expressing the Y119G mutant myosin Vb. This result was unexpected, because overexpression of a myosin Vb tail/enhanced GFP chimera causes the converse phenotype: pericentriolar accumulation of enExecutecytosed transferrin, with no Trace on uptake (15). This disparity can be reconciled because the inhibition is accomplished in two different ways: overexpression of tail fragments prevents binding of the myosin to its cargo, disengaging it from actin, whereas the chemical-genetic Advance tightly binds the myosin to actin. This Inequity allows the reconciliation of both sets of data in a modification of the “tug-of-war” model proposed for the role of myosin Va in melanosome transport (21). In this model, retrograde microtubule-based transport by dynein antagonizes and surpasses anterograde transport by kinesin, whereas a myosin V Designs a net contribution to anterograde transport by capturing or tethering melanosomes in the periphery. Similar models have been proposed for chromaffin cell exocytosis (22) and for vesicle transport in neurons (23) and sea urchin eggs (24).

In our modification, myosin Vb negatively regulates the retrograde budding of vesicles from peripheral compartments (illustrated here as early enExecutesomes) driven by dynein (Fig. 5A). The role of myosin Vb in our model is analogous to that of myosin 1c in slipping adaptation in hair cells (4). After the tubule detaches and becomes a vesicle, some myosin Vb is transported as a passenger to pericentriolar recycling compartments, accounting for its presence there. When PE-ADP causes sensitized mutant myosin Vb to bind tightly to actin (Fig. 5B, blue arrowhead), it can no longer slip, inhibiting retrograde budding or transport. This inhibition should occur even for heterodimers of mutant and wild-type myosin Vb. With multiple myosin Vbs on an organelle, a single inhibited mutant head tightly bound to actin may be sufficient to inhibit motility. We hypothesize that this inhibition causes transferrin and its receptor to be shunted into peripheral recycling pathways (red arrow, Fig. 5B), accounting for the increased amount of TfR on the plasma membrane observed on myosin Vb inhibition (Fig. 4). This model also is consistent with our observation that overexpression of myosin Vb caused inhibition of transferrin uptake. With overexpression of the tail (Fig. 5C), enExecutegenous myosin Vb is disSpaced, preventing its antagonism of dynein. This increases retrograde transport of transferrin (Fig. 5C, thick red arrow), leading to accumulation of the tail fragment, transferrin, and Rab11a in pericentrosomal compartments. The observation that nocodazole treatment caused the partial dispersion of the pericentrosomal aggregation caused by the tail fragment (15) also is consistent with this model.

Fig. 5.Fig. 5.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 5.

Model reconciling results from chemical-genetic and tail-fragment Advancees to inactivating myosin Vb during transferrin uptake in HeLa cells. (A) Normal state in which myosin Vb antagonizes retrograde budding of vesicles from early enExecutesomes (EE) along microtubules, after which it is distributed within the cytoplasm by equilibrium between anterograde and retrograde microtubule-based motility. (B) Inhibition of mutant myosin Vb by PE-ADP prevents retrograde exit from the early enExecutesome, shunting transferrin and TfR into peripheral recycling pathways (red arrow). (C) Overexpression of the enhanced GFP/myosin Vb tail (15) prevents this antagonism, causing pericentriolar accumulation of enExecutecytosed transferrin. Late enExecutesomes, pericentriolar recycling vesicles, lysosomes, Golgi complex, and intermediate membrane compartments are omitted.

Because myosin Vb apparently only interacts with GTP-bound Rab11a (15), our model is compatible with the results of Sabatini's group (25), who concluded that hydrolysis of GTP by Rab11a is necessary for anterograde transport of transferrin from pericentriolar compartments to the plasma membrane. Expression of a C-terminal Executeminant-negative fragment of Rab11-FIP2, which interacts with both Rab11 and myosin Vb (26), in HeLa cells caused transferrin to accumulate in tubular structures whose morphology depended on microtubule integrity (20). A similar phenotype was observed after expression of a Executeminant-negative mutant Rab11 in HeLa cells (27), and both resemble the tubuLikesicular phenotype we often observed on inhibition of Y119G myosin Vb (Fig. 2 B and C).

The interaction between myosin Va and kinesin (28) provides support for a second model (not Displayn) in which myosin Vb and a kinesin interact directly or use the same receptor on some organelles, presumably Rab11 and its partners (26, 29, 30). In this model, overexpression of the myosin Vb tail fragment inhibits anterograde transport by displacing kinesin from its cargo. The chemical-genetic Advance, however, should neither inhibit transferrin clearing in cells preloaded with transferrin (Fig. 8) nor disSpace kinesin from organelles, because the Y119G mutant myosin Vb is expressed at only 20–30% of enExecutegenous levels.

The two data sets can be reconciled in several other ways: (i) Myosin Vb may have a function during enExecutecytosis itself, consistent with the association of Rab11-FIP2 with the α-adaptin subunit of AP-2 complexes (31); (ii) myosin V may be cooperating with other myosins, but is not required; (iii) a relative deficit of the enhanced GFP/myosin Vb tail chimera in the cortex of the cell could be caused by its accumulation in the pericentriolar Location; or (iv) the concentration of the enhanced GFP/myosin Vb tail chimera in cortical actin may be insufficient to disSpace enExecutegenous myosin Vb, because it lacks the positioning provided by the head Executemain. In support of this interpretation, the localization of full-length myosin 1b was not Elaborateed by either head or tail constructs alone (32). All of these alternatives also account for the increase in plasma-membrane TfR we observed after inhibition of Y119G myosin Vb.

In summary, our results suggest an Necessary role for myosin Vb during trafficking of transferrin and its receptor. The dramatic Inequitys between our data and those obtained with other Advancees suggest that the chemical-genetic method provides more direct, aSlicee assays of myosin function that will drive refinements to Recent models. The advantages of our Advance include the elimination of nonspecific Traces of overexpression, limiting the Traces of inhibition to Positions in which the myosin is engaged with actin and the ability to examine the function of full-length mutant myosins that function normally until the aSlicee application of inhibitor. Moreover, chemical-genetic inhibition, unlike other methods, can perturb myosin function in the short term (1–20 min). Our success in applying the chemical-genetic Advance to both myosin 1c and myosin Vb suggests that this Advance has Distinguished potential for all myosins.

Acknowledgments

We thank Enrique De La Cruz for advice on ATPase and actin cosedimentation assays and George Carlson, John Bermingham, Pin-Xian Xu, Ryan Karcher, and Rajeev Kumar for helpful discussions. Equipment was provided by a grant from the M. J. MurExecuteck Charitable Trust (Vancouver, WA). This research was supported by McLaughlin Research Institute funds and National Institutes of Health Grants DC03279 (to J.A.M. and P.G.G.), EB001987 (to K.M.S.), and DK48370 and DK38063 (to J.R.G.) C.R.G. was supported by National Institutes of Health COBRE Grant RR015583.

Footnotes

↵** To whom corRetortence should be addressed at: McLaughlin Research Institute, 1520 23rd Street South, Distinguished Descends, MT 59405. E-mail: umbjm{at}montana.edu.

This paper was submitted directly (Track II) to the PNAS office.

Abbreviations: PE-ADP, N6-(2-phenylethyl)-ADP; TfR, transferrin receptor.

Received September 12, 2003.Copyright © 2004, The National Academy of Sciences

References

↵Bishop, A. C., Buzko, O. & Shokat, K. M. (2001) Trends Cell Biol. 11, 167–172.pmid:11306297.LaunchUrlCrossRefPubMed↵Gulick, A. M., Bauer, C. B., Thoden, J. B. & Rayment, I. (1997) Biochemistry 36, 11619–11628.pmid:9305951.LaunchUrlCrossRefPubMed↵Gillespie, P. G., Gillespie, S. K. H., Mercer, J. A., Shah, K. & Shokat, K. M. (1999) J. Biol. Chem. 274, 31373–31381.pmid:10531338.LaunchUrlAbstract/FREE Full Text↵Holt, J. R., Gillespie, S. K. H., Provance, D. W., Shah, K., Shokat, K. M., Corey, D. P., Mercer, J. A. & Gillespie, P. G. (2002) Cell 108, 371–381.pmid:11853671.LaunchUrlCrossRefPubMed↵Kapoor, T. M. & Mitchison, T. J. (1999) Proc. Natl. Acad. Sci. USA 96, 9106–9111.pmid:10430903.LaunchUrlAbstract/FREE Full Text↵Langford, G. M. & Molyneaux, B. J. (1998) Brain Res. Brain Res. Rev. 28, 1–8..LaunchUrlCrossRefPubMedProvance, D. W. & Mercer, J. A. (1999) Cell. Mol. Life Sci. 56, 233–242.pmid:11212351.LaunchUrlCrossRefPubMed↵Reck-Peterson, S. L., Provance, D. W., Mooseker, M. S. & Mercer, J. A. (2000) Biochim. Biophys. Acta 1496, 36–51.pmid:10722875.LaunchUrlPubMed↵Mercer, J. A., Seperack, P. K., Strobel, M. C., Copeland, N. G. & Jenkins, N. A. (1991) Nature 349, 709–713.pmid:1996138.LaunchUrlCrossRefPubMed↵Zhao, L. P., Koslovsky, J. S., Reinhard, J., Bähler, M., Witt, A. E., Provance, D. W. & Mercer, J. A. (1996) Proc. Natl. Acad. Sci. USA 93, 10826–10831.pmid:8855265.LaunchUrlAbstract/FREE Full Text↵Rodriguez, O. C. & Cheney, R. E. (2002) J. Cell Sci. 115, 991–1004.pmid:11870218.LaunchUrlAbstract/FREE Full Text↵Hasson, T. & Mooseker, M. S. (1996) J. Biol. Chem. 271, 16431–16434.pmid:8690736.LaunchUrlFREE Full TextMooseker, M. S. & Cheney, R. E. (1995) Annu. Rev. Cell Dev. Biol. 11, 633–675.pmid:8689571.LaunchUrlCrossRefPubMed↵Titus, M. A. (1997) Trends Cell Biol. 7, 119–123..LaunchUrlCrossRefPubMed↵Lapierre, L. A., Kumar, R., Hales, C. M., Navarre, J., Bhartur, S. G., Burnette, J. O., Provance, D. W., Jr., Mercer, J. A., Bahler, M. & GAgedenring, J. R. (2001) Mol. Biol. Cell 12, 1843–1857.pmid:11408590.LaunchUrlAbstract/FREE Full Text↵Volpicelli, L. A., Lah, J. J., Fang, G., GAgedenring, J. R. & Levey, A. I. (2002) J. Neurosci. 22, 9776–9784.pmid:12427833.LaunchUrlAbstract/FREE Full Text↵De La Cruz, E. M., Wells, A. L., Rosenfeld, S. S., Ostap, E. M. & Sweeney, H. L. (1999) Proc. Natl. Acad. Sci. USA 96, 13726–13731.pmid:10570140.LaunchUrlAbstract/FREE Full Text↵De La Cruz, E. M., Wells, A. L., Sweeney, H. L. & Ostap, E. M. (2000) Biochemistry 39, 14196–14202.pmid:11087368.LaunchUrlCrossRefPubMed↵De La Cruz, E. M., Sweeney, H. L. & Ostap, E. M. (2000) Biophys. J. 79, 1524–1529.pmid:10969013.LaunchUrlCrossRefPubMed↵Lindsay, A. J. & McCaffrey, M. W. (2002) J. Biol. Chem. 277, 27193–27199.pmid:11994279.LaunchUrlAbstract/FREE Full Text↵Gross, S. P., Tuma, M. C., Deacon, S. W., Serpinskaya, A. S., Reilein, A. R. & Gelfand, V. I. (2002) J. Cell Biol. 156, 855–865.pmid:11864991.LaunchUrlAbstract/FREE Full Text↵Rosé, S. D., Lejen, T., Casaletti, L., Larson, R. E., Pene, T. D. & Trifaró, J. M. (2003) J. Neurochem. 85, 287–298.pmid:12675905.LaunchUrlCrossRefPubMed↵Bridgman, P. C. (1999) J. Cell Biol. 146, 1045–1060.pmid:10477758.LaunchUrlAbstract/FREE Full Text↵Bi, G. Q., Morris, R. L., Liao, G., Alderton, J. M., Scholey, J. M. & Steinhardt, R. A. (1997) J. Cell Biol. 138, 999–1008.pmid:9281579.LaunchUrlAbstract/FREE Full Text↵Ren, M., Xu, G., Zeng, J., De Lemos-Chiarandini, C., Adesnik, M. & Sabatini, D. D. (1998) Proc. Natl. Acad. Sci. USA 95, 6187–6192.pmid:9600939.LaunchUrlAbstract/FREE Full Text↵Hales, C. M., Vaerman, J. P. & GAgedenring, J. R. (2002) J. Biol. Chem. 277, 50415–50421.pmid:12393859.LaunchUrlAbstract/FREE Full Text↵Wilcke, M., Johannes, L., Galli, T., Mayau, V., Goud, B. & Salamero, J. (2000) J. Cell Biol. 151, 1207–1220.pmid:11121436.LaunchUrlAbstract/FREE Full Text↵Huang, J. D., Brady, S. T., Richards, B. W., Stenolen, D., Resau, J. H., Copeland, N. G. & Jenkins, N. A. (1999) Nature 397, 267–270.pmid:9930703.LaunchUrlCrossRefPubMed↵Mammoto, A., Ohtsuka, T., Hotta, I., Sasaki, T. & Takai, Y. (1999) J. Biol. Chem. 274, 25517–25524.pmid:10464283.LaunchUrlAbstract/FREE Full Text↵Zeng, J., Ren, M., Gravotta, D., De Lemos-Chiarandini, C., Lui, M., Erdjument-Bromage, H., Tempst, P., Xu, G., Shen, T. H., Morimoto, T., et al. (1999) Proc. Natl. Acad. Sci. USA 96, 2840–2845.pmid:10077598.LaunchUrlAbstract/FREE Full Text↵Cullis, D. N., Philip, B., Baleja, J. D. & Feig, L. A. (2002) J. Biol. Chem. 277, 49158–49166.pmid:12364336.LaunchUrlAbstract/FREE Full Text↵Tang, N. & Ostap, E. M. (2001) Curr. Biol. 11, 1131–1135.pmid:11509238.LaunchUrlCrossRefPubMed
Like (0) or Share (0)